Shasha Wang

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 4

Top Topics

Randomized Controlled Trial

Systemic Lupus Erythematosus

Bioinformatics Analysis

Diffuse Large B Cell Lymphoma

Top Venues

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Liyuan Dai, Haizhu Chen, Qiaoyun Tan, Yanrong Wang, Lin Li, Ning Lou, Guangyu Fan, Tongji Xie, Rongrong Luo, Shasha Wang, Yu Zhou, Qiaofeng Zhong, Jiarui Yao, Zhishang Zhang, Le Tang, Yuan-Kai Shi, Xiao-Hong Han
Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray. Cancer (2023)
Liyuan Dai, Haizhu Chen, Qiaoyun Tan, Yanrong Wang, Lin Li, Ning Lou, Guangyu Fan, Tongji Xie, Rongrong Luo, Shasha Wang, Yu Zhou, Qiaofeng Zhong, Jiarui Yao, Zhishang Zhang, Le Tang, Yuan-Kai Shi, Xiao-Hong Han
Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray. Cancer 130 (8) (2023)
Liyuan Dai, Haizhu Chen, Qiaoyun Tan, Yanrong Wang, Lin Li, Ning Lou, Guangyu Fan, Tongji Xie, Rongrong Luo, Shasha Wang, Yu Zhou, Qiaofeng Zhong, Jiarui Yao, Zhishang Zhang, Le Tang, Yuan-Kai Shi, Xiao-Hong Han
Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray. Cancer 130 (8) (2023)
Shasha Wang, Rongrong Luo, Yuan-Kai Shi, Xiaohong Han
The impact of the ALK fusion variant on clinical outcomes in EML4-ALK patients with NSCLC: a systematic review and meta-analysis. Future oncology (London, England) (2021)